In the same vein, we observed a lower prevalence of ERBB2 amplification in this breast cancer patient cohort compared to that in a general population (3 vs. 10–15%, respectively) but a higher incidence of ESR1 mutations (Supplementary Figure 3) associated with progression on hormone-based therapies. Here, ESR1 is linked to breast cancer.